Biological Evaluation of the NIR‐Emissive Ruby Analogue [Cr(ddpd)2][BF4]3 as a Photodynamic Therapy Photosensitizer. Issue 1 (8th November 2018)

• Record Type: Journal Article
• Authors: Basu, Uttara; Otto, Sven; Heinze, Katja; Gasser, Gilles
• Is Part Of: European journal of inorganic chemistry. Issue 1(2019)
• Page Start: 37
• Page End: 41
• Publication Date: 2018-11-08
• Subjects: Chromium -- Cytotoxicity -- Photocytotoxicity -- Photodynamic therapy -- Singlet oxygen; Chemistry, Inorganic -- Periodicals; Organometallic chemistry -- Periodicals; Bioinorganic chemistry -- Periodicals; Solid state chemistry -- Periodicals; 546
• DOI: 10.1002/ejic.201801023
• Languages: English
• ISSNs: 1434-1948

Abstract

Abstract : Photodynamic therapy relies on the bioavailability of photosensitizers with suitable photophysical, chemical, and biochemical properties. Although the photophysical properties, stability, and high water solubility of the chromium(III) complex [Cr(ddpd)2 ][BF4 ]3 (ddpd = N, N′ ‐dimethyl‐ N, N′ ‐dipyridin‐2‐ylpyridine‐2, 6‐diamine) are very favorable, its photocytotoxicity against cancerous and non‐cancerous cell lines has not yet been elucidated. We now report the cytotoxicity and photocytotoxicity of the complex [Cr(ddpd)2 ][BF4 ]3 against human cervical cancer cells, human primary glioblastoma cells, human glioblastoma astrocytoma cells, and non‐cancerous retinal pigment epithelium cells. Abstract : The efficacy of a luminescent chromium(III) complex with a long excited state lifetime has been investigated for photodynamic therapy applications in vitro.